Alizadeh Narges; Oskuee Alireza Ba–Eeman; Golchai Javad; Sadre-Eshkevari Shahryar; Darjani Abbas; Kazemnejad Ehsan; Eftekhari Hojat; Mohtasham-Amiri Zahra
Volume 17, Issue 2 , 2014, , Pages 54-58
Abstract
Background: Methicillin–resistant Staphylococcus aureus (MRSA)has recently emerged as a worldwide major nosocomial pathogenthat causes significant morbidity and mortality. MRSA is frequentlycolonized on the skin. The aim of this study was to determinethe MRSA colonization/infection prevalence and ...
Read More
Background: Methicillin–resistant Staphylococcus aureus (MRSA)has recently emerged as a worldwide major nosocomial pathogenthat causes significant morbidity and mortality. MRSA is frequentlycolonized on the skin. The aim of this study was to determinethe MRSA colonization/infection prevalence and to evaluatethe potential risk factors for its development in the hospitalizedpatients in a referral dermatology ward.Method: In this cross sectional study, 203 patients with cutaneouslesions who were admitted to the dermatology ward of a tertiaryteaching hospital from 2008 to 2010 were recruited. Sampleswere collected during the first 48 hours of admission. S. aureuswas identified using gram staining, catalase, and coagulase tests.The disk diffusion method was used for testing the sensitivityof different bacteria to antibiotics. Mueller-Hinton agar was theculture medium used for MRSA susceptibility testing.Result: Staphylococcus. aureus was the most common pathogenthat grew in 56.2% (114/203) of isolates. MRSA was foundin 35.5% (82/203) of isolates. The duration of the cutaneouslesions, age group, positive history of antibiotic use in past 12months, and underlying diseases were statistically differentbetween the patients with colonization of MRSA and methicillinsensitiveStaphylococcus aureus (MSSA) (P
MA Nilfroush Zadeh; N Anasri; R Derakhshan
Volume 8, Issue 6 , 2006, , Pages 457-461
Abstract
Background and aim: Pentavalent antimony compounds are the first line treatment for cutaneous leishmaniasis. Clinical resistance to pentavalent antimony in the form of meglumine antimoniate (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime were studied ...
Read More
Background and aim: Pentavalent antimony compounds are the first line treatment for cutaneous leishmaniasis. Clinical resistance to pentavalent antimony in the form of meglumine antimoniate (Glucantime) has been recognized as a problem in leishmaniasis. Herein, clinical response to Glucantime were studied in patients suffered from cutaneous leishmaniasis.Materials and Methods: In a cross-sectional study 370 patients with cutaneous leishmaniasis were treated with systemic Glucantime, 50 mg/kg/day, for 2 to 3 weeks. They were visited weekly for 3 weeks and also followed up for 3 months after treatment was completed. The clinical and parasitological response to this treatment was evaluated, and classified into partial and complete response and failure to treatment. Results: Two hundred forty-seven men and 123 women were followed up. The mean age was 36.7±16 years. There were 64.1% partial response after 2 weeks and 73% partial response at the third week of treatment. 11.6% of lesions were not cured after 3 weeks of treatment and 8.1% were not still cured 12 weeks thereafter.Conclusion: Clinical resistance to Glucantime is an important problem. The mechanisms of resistance and using drug combinations are needed to be considered.